Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
Steen Dalby Kristensen, a cardiologist with Aarhus University Hospital in Denmark, detailed some of the hottest topics at the European Society of Cardiology's annual meeting.
The ILUMIEN IV and OCTOBER trials helped illustrate that the benefits of intravascular ultrasound also are seen with optical coherence tomography. Both trials were included in the new meta-analysis presented at ESC Congress 2023.
Researchers think their findings, which were presented at ESC Congress 2023 and published in the New England Journal of Medicine, could "change the nature of the conversation about the role of obesity in HFpEF."
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
